SweetValueLab
Write for us

Revvity, Inc. — Wall Street Analyst Estimates & Price Targets

RVTY
NYSEHealthcareMedical - Diagnostics & ResearchCIK 0000031791revvity.comAbout RVTY
Last close · Oct 16, 2026152.64−2.07 (−1.34%)
Market cap$17.0B

4 firms' latest targets, last 90 days: median $150.00 ($135.00–$165.00), 2% below the last close.

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker
$80.0$100$120$140$160NovJan 2026MarMayJulSep2025-10-24 · Baird: $1222025-10-27 · Evercore ISI: $1082025-10-28 · Baird: $1232025-10-28 · Barclays: $1052025-12-09 · Goldman Sachs: $1052025-12-15 · Wells Fargo: $1072025-12-15 · Barclays: $1152026-02-02 · Jefferies: $1052026-02-03 · Baird: $1292026-02-03 · TD Cowen: $1242026-02-03 · Evercore ISI: $1182026-02-03 · Barclays: $1182026-04-14 · Barclays: $95.02026-05-04 · Baird: $1252026-05-06 · Stifel: $1002026-05-06 · Baird: $1172026-06-26 · Bernstein: $1152026-07-06 · Evercore ISI: $1252026-09-01 · RBC Capital: $1352026-09-04 · KeyBanc: $1652026-09-09 · UBS: $1402026-10-07 · Barclays: $160
$80.0$100$120$140$160NovFebMayAug

Each firm's latest target

last 90 days · 4 firms
DateFirmTargetPreviousChangeVs price thenVs price now
2026-10-07Barclays$160.00$95.00▲ 68%+4%+5%
2026-09-09UBS$140.00——+10%-8%
2026-09-04KeyBanc$165.00——+26%+8%
2026-09-01RBC Capital$135.00——+5%-12%

Consensus estimates

revenue and EPS by fiscal year · reported years marked
FYRevenueYoYEPSYoYRevenue rangeEPS rangeAnalysts
2023reported$2.8B-17%$5.55+23%est. $2.7B+2%est. $1.604
2024reported$2.8B+0%$2.20-60%est. $2.8B+0%est. $4.859
2025reported$2.9B+4%$2.07-6%est. $2.8B+0%est. $4.949
2026$2.9B+0%$5.36+8%$2.8B–$2.9B$5.35–$5.4012
2027$3.0B+5%$5.89+10%$3.0B–$3.0B$5.83–$5.9212
2028$3.2B+6%$6.46+10%$3.1B–$3.2B$4.70–$8.9910
2029$3.4B+7%$7.08+9%$3.4B–$3.4B$7.01–$7.167
2030$3.6B+5%$7.72+9%$3.6B–$3.6B$7.65–$7.817
A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.